YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

In Vitro Selection of MRSA Strains Resistant to Some New Fluoroquinolone Antibiotics and Characterization of their Resistance Mechanisms

새로운 플루오로 퀴놀론계 항균제에 대한 내성 MRSA 균주의 In Vitro 선발과 그 내성 기전 분석

  • Yoon, Eun-Jeong (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kim, Hyun-Jee (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Lee, Chun-Yeong (Department of Life Science, University of Seoul) ;
  • Choi, Eung-Chil (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Shim, Mi-Ja (Department of Life Science, University of Seoul)
  • 윤은정 (서울대학교 약학대학종합 약학 연구소) ;
  • 김현지 (서울대학교 약학대학종합 약학 연구소) ;
  • 이춘영 (서울시립대학교 생명과학과) ;
  • 최응칠 (서울대학교 약학대학종합 약학 연구소) ;
  • 심미자 (서울시립대학교 생명과학과)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Clinically isolated methicillin-resistant Staphylococcus aureus strains were exposed to subinhibitory concentration of DW286, DW-224a, gemifloxacin, trovafloxacin, sparfloxacin and ciprofloxacin during 26- to 39-days period. Subculturing led to resistance development, and most of the selected mutants were above susceptible breakpoints. Selected mutants had broad cross resistance to other quinolone antibiotics and only one mutant was completely susceptible to all fluoroquinolones. Twenty five among 42 mutants revealed mutations on DNA gyrase and topoisomerase IV by sequencing. Also 16 mutants had fluoroquinolones MICs that were 4-32 times lower in the presence of reserpine. In conclusion, alterations in DNA gyrase or topoisomerase IV and action of efflux pumping out system are the resistance mechanisms of DW-224a.

Keywords

References

  1. Chanbers, H. F. : The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7, 178 (2001) https://doi.org/10.3201/eid0702.010204
  2. Daum, R. S. and Seal, J. B. : Evolving antimicrobial chemotherapy for Staphylococcus aureus infection: our backs to the wall. Crit. Care Med. 29 Suppl 4, N92 (2001) https://doi.org/10.1097/00003246-200104001-00007
  3. Piddock, L. J. V. : Newer fluoroquinolones and Gram positive bacteria. ASM News 59, 603 (1993)
  4. Acar, J. F. and Francoual, S. : The clinical problems of bacterial resistance to the new quinolones. J. Antimicrob. Chemother. 26 Suppl B, 207 (1990) https://doi.org/10.1093/jac/26.suppl_B.207
  5. Hamett, N., Brown, S. and Krishnan, C. : Emergence of quinolone resistance among clinical isolate of methicillinresistant Staphylococcus aureus in Ontario, Canada. Antimicrob. Agents Chemother. 35, 1911 (1991) https://doi.org/10.1128/AAC.35.9.1911
  6. Tanaka, M., Wang, T., Onodera, Y., Uchida, Y. and Sato, K. : Mechanisms of quinolone resistance in Staphylococcus aureus. J. Infect. Chemother. 6, 131 (2000) https://doi.org/10.1007/s101560070010
  7. Piddock, L. J. : Mechanisms of fluoroquinolone resistance: and update 1994-1998. Drugs 58 Suppl 2, 11 (1999)
  8. Park, H. S., Kim, H. J., Seol, M. J., Choi, D. R., Choi, E. C. and Kwak, J. H. : In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone Antimicrob. Agents Chemother. 50, 2261 (2006) https://doi.org/10.1128/AAC.01407-05
  9. Kosowska-Shick, K., Credito, K., Pankuch, G. A., Lin, Gengrong., Bozdogzn, B., McGhee, P., Dewasse, B., Choi, D. R., Ryu, J. M. and Appelbaum, P. C. : Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrob. Agents Chemother. 50, 2064 (2006) https://doi.org/10.1128/AAC.00153-06
  10. Kwon, A. R., Min, Y. H., Ryu, J. M., Choi, D. R., Shim, M. J. and Choi, E. C. : In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J. Antimicrob. Chemother. 58, 684 (2006) https://doi.org/10.1093/jac/dkl304
  11. Ince, D. and Hooper, D. C. : Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44, 3344 (2000) https://doi.org/10.1128/AAC.44.12.3344-3350.2000
  12. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; 15th informational Supplement. Document M100-S15, CLSI, Wayne, PA (2005)
  13. Kim, M. J., Yun, H. J., Kang, J. W., Kim, S., Kwak, J. H. and Choi, E. C. : In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates. J. Antimicrob. Chemother. 51, 1011 (2003) https://doi.org/10.1093/jac/dkg162
  14. Aeschlimann ,J. R., Dresser, L. D., Kaatz, G. W. and Rybak, M. J. : Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 43, 335 (1999)
  15. Yoshida, H., Bogaki, M., Nakamura, M., Yamanaka, L. M. and Nakamura, S. : Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35, 1647 (1991) https://doi.org/10.1128/AAC.35.8.1647
  16. Weigel, L. M., Anderson, G. J., Facklam, R. R. and Tenover, F. C. : Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45, 3517 (2001) https://doi.org/10.1128/AAC.45.12.3517-3523.2001